Literature DB >> 27804217

Acute myeloid leukemia therapy elicits durable complete response in chemoradio-resistant metastatic paraganglioma.

Sameer Sait1, Rachel Kobos1, Michael P LaQuaglia1, Neeta Pandit-Taskar2, Shakeel Modak1.   

Abstract

Few effective therapeutic options exist for patients with metastatic paraganglioma (PGL). We report the case of a 16-year-old male who developed acute myeloid leukemia (AML) 30 months following the treatment for metastatic PGL. PGL had been refractory to 131 I-meta-iodobenzylguanidine and temozolomide therapy. However, there was a major reduction in primary tumor allowing its gross total resection, and complete resolution of metastatic disease following AML-directed therapy that included daunorubicin, cytarabine, and etoposide. He remains in remission for both AML and PGL, 48 months post AML chemotherapy. Alternative chemotherapeutic agents should be considered for metastatic PGL resistant to conventional therapy.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  acute myeloid leukemia; chemotherapy; metastatic paraganglioma

Mesh:

Substances:

Year:  2016        PMID: 27804217      PMCID: PMC5535780          DOI: 10.1002/pbc.26314

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  20 in total

1.  Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group.

Authors:  W G Woods; N Kobrinsky; J D Buckley; J W Lee; J Sanders; S Neudorf; S Gold; D R Barnard; J DeSwarte; K Dusenbery; D Kalousek; D C Arthur; B J Lange
Journal:  Blood       Date:  1996-06-15       Impact factor: 22.113

2.  Palliative chemotherapy for malignant pheochromocytoma: symptomatic palliation of two cases.

Authors:  M Iwabuchi; Y Oki; H Nakamura
Journal:  Intern Med       Date:  1999-05       Impact factor: 1.271

3.  Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the Childrens Cancer Study Group.

Authors:  J D Buckley; R L Chard; R L Baehner; M E Nesbit; B C Lampkin; W G Woods; G D Hammond
Journal:  Cancer       Date:  1989-04-15       Impact factor: 6.860

Review 4.  Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis.

Authors:  N D Niemeijer; G Alblas; L T van Hulsteijn; O M Dekkers; E P M Corssmit
Journal:  Clin Endocrinol (Oxf)       Date:  2014-07-30       Impact factor: 3.478

5.  Pheochromocytoma and paraganglioma in children: a review of medical and surgical management at a tertiary care center.

Authors:  Tuan H Pham; Christopher Moir; Geoffrey B Thompson; Abdalla E Zarroug; Chad E Hamner; David Farley; Jon van Heerden; Aida N Lteif; William F Young
Journal:  Pediatrics       Date:  2006-09       Impact factor: 7.124

6.  Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine.

Authors:  Alberto Garaventa; Claudio Gambini; Giampiero Villavecchia; Andrea Di Cataldo; Luigi Bertolazzi; Maria Rosa Pizzitola; Bruno De Bernardi; Riccardo Haupt
Journal:  Cancer       Date:  2003-03-01       Impact factor: 6.860

Review 7.  Pheochromocytoma and Paraganglioma: Genetics, Diagnosis, and Treatment.

Authors:  Lauren Fishbein
Journal:  Hematol Oncol Clin North Am       Date:  2015-10-23       Impact factor: 3.722

8.  Multiple pulmonary chemodectomas in a child: results of four different therapeutic regimens.

Authors:  S N Chow; M Seear; R Anderson; F Magee
Journal:  J Pediatr Hematol Oncol       Date:  1998 Nov-Dec       Impact factor: 1.289

9.  Secondary hematological malignancies associated with temozolomide in patients with glioma.

Authors:  Hiroyuki Momota; Yoshitaka Narita; Yasuji Miyakita; Soichiro Shibui
Journal:  Neuro Oncol       Date:  2013-03-21       Impact factor: 12.300

10.  Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.

Authors:  Håkon Reikvam; Kimberley Joanne Hatfield; Astrid Olsnes Kittang; Randi Hovland; Øystein Bruserud
Journal:  J Biomed Biotechnol       Date:  2011-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.